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Abstract
Patients considering living donor liver transplantation (LDLT) need to know the risk and severity
of complications compared to deceased donor liver transplantation (DDLT). One aim of the Adult-
to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) was to examine recipient
complications following these procedures. Medical records of DDLT or LDLT recipients who had
a living donor evaluated at the nine A2ALL centers between 1998 and 2003 were reviewed.
Among 384 LDLT and 216 DDLT, at least one complication occurred after 82.8% of LDLT and
78.2% of DDLT (p = 0.17). There was a median of two complications after DDLT and three after
LDLT. Complications that occurred at a higher rate (p < 0.05) after LDLT included biliary leak
(31.8% vs. 10.2%), unplanned reexploration (26.2% vs. 17.1%), hepatic artery thrombosis (6.5%
vs. 2.3%) and portal vein thrombosis (2.9% vs. 0.0%). There were more complications leading to
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retransplantation or death (Clavien grade 4) after LDLT versus DDLT (15.9% vs. 9.3%, p =
0.023). Many complications occurred more commonly during early center experience; the odds of
grade 4 complications were more than twofold higher when centers had performed ≤20 LDLT (vs.
>40). In summary, complication rates were higher after LDLT versus DDLT, but declined with
center experience to levels comparable to DDLT.
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Introduction
The introduction of right lobe adult-to-adult living donor liver transplant (LDLT) created a
new treatment option for patients in need of liver replacement. The procedure is highly
technical in nature, and has not yet achieved the widespread application of deceased donor
liver transplant (DDLT) (1). Given the comparatively recent introduction of LDLT,
comprehensive descriptions of its associated complication rates and outcomes have been
published mainly in single-center reports (2–7). The Adult-to-Adult Living Donor Liver
Transplantation Cohort Study (A2ALL) includes nine U.S. transplant centers with LDLT
experience that have collaboratively collected retrospective and prospective LDLT data.
This report details the A2ALL retrospective cohort morbidity experience among LDLT
recipients and contemporaneous patients who had potential living donors, but who
ultimately received a DDLT graft.
Methods
Data collection and conventions
Data for this study were derived from the retrospective component of the A2ALL study and
were supplemented by data from the Scientific Registry of Transplant Recipients (SRTR)
made available through a data use agreement. A2ALL data were collected based on detailed
chart reviews. Entry of a recipient into the A2ALL Retrospective Cohort Study required the
identification of a potential donor who completed a history and physical examination during
the period January 1, 1998 to February 28, 2003 at one of nine U.S. transplant centers. A
total of 819 potential adult recipients met the inclusion criteria. The current analysis
included the 600 patients who proceeded to the operating room with the intention of
receiving either a LDLT or DDLT for nonfulminant indications. Recipients whose
procedures were aborted due to recipient reasons were included (four LDLT; three DDLT).
Recipients of domino transplants (n = 2) were included in the DDLT group.
Complications were defined as unexpected events that were not inherent to the transplant
procedure. Severity of complications was graded using an adaptation of the Clavien scoring
system (8–10) for the classification of negative outcomes (Table 1).
Statistical methods
Descriptive statistics included means, standard deviations and proportions. Mantel–Haenszel
trend tests were used to compare LDLT versus DDLT for number of complications per
patient and complications by grade. Chi-square tests (and Fisher's exact tests in cases of
small cell sizes) were used to compare LDLT versus DDLT for the proportion with Clavien
grade 4 complications and for the proportion with complications of any Clavien grade. Since
similar results were obtained by log-rank tests, most events occurred during the first 30 days
and most (98% of LDLT, 96% of DDLT) follow-up times were beyond 30 days, only chi-
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square test results were reported. Logistic regression analyses were used to investigate
predictors of biliary leak, biliary stricture and Clavien grade 4 complications. Each of the
variables in Table 2 was tested in each of the logistic regression models. Results are
presented as adjusted odds ratios (AOR) and 95% confidence intervals (CI). In a previous
A2ALL analysis of mortality, LDLT recipients were classified as having received their
transplant when the center had less LDLT experience (had performed ≤20 LDLT) or more
LDLT experience (had performed >20 LDLT) (11). To test the effect of center experience
on complications using smaller increments, the sequential cases at each center were
categorized as cases 1–10, 11–20, 21–40 and greater than 40 in the logistic regression
models.
All analyses were carried out using SAS 9.1 statistical software (SAS/STAT 9.1 User's
Guide, SAS Publishing, Cary, NC: SAS Institute Inc.).
Human subjects protection
The study was approved by the Institutional Review Boards and Privacy Boards of the
University of Michigan Data Coordinating Center and each of the nine participating
transplant centers.
Results
The study group consisted of 384 LDLT and 216 DDLT recipients followed for a median of
2.1 years (range 0–5.9 years). The follow-up time for LDLT was longer than that for DDLT
(2.2 years vs. 1.9 years, respectively; log-rank p = 0.008), although this difference had little
impact on the analysis because most complications occurred within 30 days. At least 1 year
of follow-up was available for 84% of LDLT and 69% of DDLT recipients. The
characteristics of LDLT and DDLT recipients at the time of transplant are shown in Table 2.
Compared to DDLT recipients, the LDLT recipients were slightly younger (mean age 49.6
vs. 51.4 years; p = 0.037), had less advanced liver disease (mean Model for End-stage Liver
Disease [MELD] score 15 vs. 21; p < 0.0001) and were more medically stable (2% vs. 18%
in ICU; p < 0.0001) at the time of transplant. The graft weight to recipient weight ratio was
less than 0.8 in 30 cases (8%), with a range of 0.5–2.6.
Table 3 compares the frequencies of complications for early and later LDLT experience
groups (LDLT case number ≤20 and >20) and DDLT. In the early LDLT experience group,
only 9.6% of patients had no complications, compared with 23.0% among the later LDLT
experience group and 21.8% among DDLT recipients. Early LDLT experience recipients
tended to have a greater number of complications per patient, a median of four, compared to
a median of two in the later LDLT experience group (p < 0.0001) and two in the DDLT
group (p = 0.72 compared to later LDLT experience).
The specific types of complications were aggregated into three broad categories: surgical,
medical and infectious. A summary of the frequency of these complications is detailed in
Table 4. Recipients transplanted during periods of later (>20 cases) versus earlier (≤20
cases) LDLT center experience experienced a lower proportion of complications in almost
every category. Significant reductions (all p < 0.04) with increased LDLT experience were
seen with biliary leak or biloma (38% vs. 27%), unplanned reexploration (36% vs. 19%),
pneumothorax (3% vs. 0%), ascites (21% vs. 9%) and overall infections (48% vs. 33%),
particularly blood bacterial (23% vs. 14%) and fungal (5% vs. 1%) infections. Comparing
complications between the later LDLT experience group and DDLT, we still observed
significantly higher (all p < 0.04) proportions of recipients with complications after LDLT
for biliary leak or biloma (27% vs. 10%), GI bleeding (8% vs. 3%) and bile duct infections
(8% vs. 3%). However, significantly lower (all p < 0.04) proportions of recipients with
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complications were observed among the experienced LDLT group versus DDLT for
pneumothorax (0% vs. 2%), pulmonary edema (10% vs. 21%), hepatic encephalopathy (4%
vs. 10%), ascites (9% vs. 17%) and fungal pulmonary infections (1% vs. 7%). Table 4
reports 48 p-values, of which 12 are significant (p < 0.05), and 2.4 would be expected to be
significant by chance if all tests were independent.
Complications graded according to the Clavien scale (Table 1) are shown in Table 5. The
majority of complications were grade 1 or grade 2. As shown in Table 5, complications
leading to retransplantation or death (Clavien grade 4) occurred more frequently among
LDLT recipients (LDLT: n = 61 [15.9%]; DDLT: n = 20 [9.3%]; p = 0.023). Recipients with
complications that led to retransplantation were more common in the LDLT group (n = 35;
9.1%) than in the DDLT group (n = 8; 3.7%; p = 0.014). Retransplantation for vascular
complications occurred more frequently in LDLT recipients (n = 22; 5.7% vs. n = 2; 1.0%,
respectively; p = 0.004). The number of deaths, with or without retransplantation, was not
significantly different between the LDLT (n = 34; 5.6%) and DDLT (n = 14; 2.3%; p = 0.30)
groups. Although the overall proportion of recipients with biliary complications was higher
in the LDLT group, the subset with Clavien grade 4 biliary complications was not
significantly different in the two groups (p = 0.47).
The effect of center LDLT experience on the occurrence and Clavien grade of recipient
complications is shown in Table 6. The proportions of recipients who had any
complications, any biliary complications, bile leak or biloma, infection and unplanned
reexploration were significantly lower after 20 LDLT cases versus ≤20 LDLT cases. For
vascular complications, no significant difference was found after 20 LDLT cases versus ≤20
LDLT cases (7% vs. 11%, p = 0.18). Comparing complications after 20 LDLT cases versus
DDLT, the proportions with infection, unplanned reexploration and vascular complications
were not significantly different, but any biliary complication and biliary leak or biloma
remained significantly higher versus DDLT (p = 0.013 and p < 0.0001, respectively).
Center LDLT experience was associated with a significantly lower incidence of grade 4
complications overall (22% vs. 11%; p = 0.003), and a reduced but not significantly lower
incidence for each tested subtype of grade 4 complication. The Mantel–Haenszel trend test
across the range of Clavien grades was significant only for vascular complications (LDLT
case number ≤20 vs. >20: p = 0.0291; LDLT case number >20 vs. DDLT: p = 0.0024).
Because biliary complications occurred at a higher rate in LDLT recipients and were a
significant cause of morbidity, two separate logistic regression models were used to
investigate risk factors for the development of a biliary leak or of a biliary stricture among
LDLT recipients (Table 7A and B). Bivariate and multivariable analyses revealed three
variables that were significantly associated with biliary leak. In the multivariable model, a
donor with three or more bile ducts was associated with higher risk than that with one duct
(AOR = 2.72, p = 0.035) and recipient HCV diagnosis was associated with lower risk than
non-HCV (AOR = 0.55, p = 0.011). Center experience was grouped into cases 1–10, 11–20,
21–40 and >40, using case number >40 as the reference group. The risk of biliary leak
dropped monotonically with increasing experience (Table 7A). Compared to case number
>40, the risk of biliary leak was 126% higher for cases 1–10 (AOR = 2.26, p = 0.015), with
a statistically significantly decreasing trend in risk from earlier to later cases by ordinal trend
test (p = 0.012).
Two variables were significantly associated with biliary stricture (duration of recipient
operation and Roux-en-Y biliary reconstruction) in bivariate analyses. In the multivariable
logistic regression model, five variables were significant: recipient diagnosis of cholestatic
liver disease (AOR = 2.10, p = 0.040) and duration of recipient operation (AOR = 1.33 per
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100 min, p = 0.014) were associated with higher risk. Two variables were associated with a
lower risk of biliary stricture: use of a Roux-en-Y reconstruction (AOR = 0.49, p = 0.017)
and donor hypotension (AOR = 0.45, p = 0.038). Finally, as with biliary leak, there was a
significantly higher risk of biliary stricture during early center experience (Table 7B). Cold
ischemia time was not a significant predictor of either biliary leak or biliary stricture.
Predictors of grade 4 complications among LDLT and DDLT recipients were investigated in
a third logistic regression analysis (Table 7C). This model showed that patients who
underwent LDLT during a center's earlier experience (<20 LDLT) had more than two-fold
the odds of developing a grade 4 complication compared to those who underwent LDLT
once the center had done >40 LDLT cases (cases 1–10: AOR = 2.33, p = 0.036). There was
a statistically significantly decreasing trend in risk of grade 4 complications from earlier to
later cases by ordinal trend test (p = 0.008).
In a separate model of grade 4 complications restricted to LDLT recipients, each of the
donor factors in Table 2 were tested and none was found to be significant, including the
graft weight to recipient weight ratio <0.8.
There was no difference in the odds of a grade 4 complication between DDLT recipients and
LDLT recipients transplanted after centers had performed at least 40 cases (AOR = 0.78, p =
0.52). Although cold ischemia time could not be tested in this model because of
confounding with transplant type, we tested its effect in separate models for LDLT and
DDLT. In each case, longer cold ischemia time (as a continuous variable) was associated
with significantly higher odds of grade 4 complications (LDLT: AOR = 1.26/h, p = 0.005;
DDLT: AOR = 1.17/h, p = 0.009).
Discussion
Despite its introduction for pediatric patients nearly 20 years ago (12), the use of living
donors for liver transplantation in adults has emerged more slowly. Interest in adult-to-adult
LDLT increased as experience with the procedure grew in Japan and Korea, where deceased
donor organs were not readily available. The increased use of split livers in the United States
and Europe also contributed to the surgical skills needed to successfully perform the LDLT
procedure (13). Unlike living donor kidney transplantation, where advantages of living
donor over deceased donor grafts have been demonstrated in both recipient and graft
survival, and where the safety of the donor operation has been documented, LDLT is still
under a high level of scrutiny (14,15).
The A2ALL network was established to better assess the safety of the LDLT procedure for
both donors and recipients, and to better define the situations where the procedure should be
considered as an option. One primary study aim was to establish the rates of various
complications for both donors and recipients in order to properly inform patients as they
make decisions relating to the pursuit of living donor transplant. An important finding from
the A2ALL group was the demonstration of a significant survival benefit for potential
recipients when they chose to pursue living donor transplant versus remaining on the waiting
list for DDLT (16). This advantage was most clear after the transplant center had done at
least 20 LDLT procedures. A lingering question, however, has been the rate of
complications experienced by recipients of the LDLT, and how these rates compare with
DDLT. This report is the first to compare the two groups, using a cohort of recipients who
all shared the common feature of having at least one donor who completed a history and
physical examination for potential LDLT.
In this and other series, LDLT recipients were less ill in general than their DDLT
counterparts at the time of transplantation. In the early reported experience with LDLT, it
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was observed that patients who had more decompensated liver disease did less well with
LDLT (17). In the period of time covered by our study, two different organ allocation
schemes for DDLT were in effect, the older system utilizing hospital or ICU status and
Child-Turcotte-Pugh score to determine ranking on the waiting list, and the MELD system
since February 2002. Although our LDLT and DDLT recipients were comparable at study
enrollment, which was the date of the potential donor's history and physical examination
(16), MELD score at the time of transplant was higher in recipients of DDLT, since the
latter group had a longer time until transplant. A significantly higher proportion of DDLT
recipients were in the ICU and/or on dialysis at the time of transplant. This may explain the
higher infection rates in DDLT recipients, since they had longer and possibly more complex
pretransplant hospital stays.
The most important differences in posttransplant morbidity between recipients of LDLT and
DDLT were seen in surgical complications. Biliary complications (especially biliary leak),
vascular complications and unplanned reexplorations were observed at higher frequencies in
LDLT recipients. Other authors have noted higher biliary and vascular complication rates
among LDLT recipients compared to historic DDLT controls (18). Possible explanations
include the greater technical demands of LDLT, inferior quality of the LDLT graft and the
caliber of LDLT donor vessels available for anastomosis (19–25). An added dimension of
this study was the systematic use of the Clavien grading system to characterize the severity
of complications. In our analyses, these surgical complications led to a higher rate of
retransplantation and death (Clavien grade 4) among LDLT recipients compared to DDLT
recipients. The overall rate of biliary complications in LDLT recipients was 42.2% versus
24.5% in DDLT recipients, and many of these complications required repeated endoscopic
or percutaneous transhepatic interventions. Such information should be helpful when
counseling patients about the option of LDLT.
Possible explanations for the higher rate of biliary complications after LDLT (and proposed
solutions) have been described (26,27). One study characterized preoperative and
intraoperative findings that were associated with a higher rate of biliary complications (28).
In the current study, certain technical details of the biliary reconstruction were captured.
Having three or more bile ducts in the liver graft was associated with higher risk of biliary
leak. Preoperative imaging and determination of the planned line of transection through the
liver may permit predictions about the number of ducts that may require anastomosis. If the
proposed graft is expected to yield three or more ducts, consideration could be given to
selecting a different donor, or at least counseling the recipient about the higher risk of leak.
In terms of biliary stricture, the use of a Roux-en-Y anastomosis was associated with a lower
odds of stricture formation, as was donor hypotension. We are unable to ascribe a causative
relationship between the anastomotic technique and the occurrence of biliary stricture, since
the choice of technique is often dictated by operative findings. The best technique for
reconstruction continues to be a topic of debate (29–32), and given limited details in our
retrospective data collection, it may be premature to suggest that a Roux-en-Y should be
done in every case. The basis for the association between biliary stricture and donor
hypotension is unclear. Data currently being collected in the A2ALL Prospective Cohort
Study may illuminate both of these issues in the future.
The level of experience with a procedure, especially one as complicated as LDLT, should be
considered in analyses of outcomes. Thus, in the current study, the adjusted odds of a biliary
leak or stricture were higher when centers had not yet performed 40 LDLT. The rate of
biliary stricture after DDLT, for which techniques of biliary reconstruction are well
established, has been reported in 10–30% of recipients. This suggests that the rate of this
complication after LDLT may be difficult to reduce further (33). The inability to accurately
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assess the viability of biliary tissue at the time of anastomosis may contribute to this
problem.
Another important finding related to center experience was the lack of difference in the odds
of Clavien grade 4 complications (defined as leading to retransplantation or death) between
DDLT and LDLT recipients once the center had performed more than 20 LDLT cases. This
finding is consistent with the improved survival seen with LDLT in experienced centers
versus remaining on the waitlist for a DDLT (16). In both LDLT and DDLT, we found a
significant relationship between cold ischemia time and the likelihood of grade 4
complications. This is consistent with our previous identification of cold ischemia time as a
significant predictor of the overall risk of LDLT graft failure, and further emphasizes the
unique importance of even the comparatively short cold ischemia times associated with
LDLT transplantation (11). When patients are evaluated and treatment options are reviewed,
these aspects should be considered by the patient and caregivers in the decision whether to
proceed with LDLT.
We have previously shown that graft size in the A2ALL retrospective cohort was not
associated with a significantly higher risk of graft failure (11), and in the current study, the
low graft weight to recipient weight ratio (<0.8) was not a significant predictor of bile leak,
biliary stricture or grade 4 complications.
Many advances in LDLT have occurred over the last decade, but its exact place in the
treatment armamentarium for patients with end-stage liver disease and liver cancer is still
being defined. This study not only provided details on complications of liver transplantation
but also defined complications that are more frequent in LDLT. Despite a higher rate of
complications among LDLT recipients, complications requiring retransplantation or leading
to death were not significantly higher in LDLT once centers were experienced with the
procedure. This finding, in concert with our previous conclusion that choosing LDLT over
continuing on the waitlist leads to a survival advantage in experienced centers, underscores
the impact of the learning curve on this highly technical procedure. Potential LDLT
recipients need to hear about the rates of complications, and this study will help to define
those rates. The decision to proceed, however, must be balanced against the possibility of
deteriorating or dying while on the waitlist. We acknowledge that in this study the LDLT
recipients had relatively low MELD score at transplant and our results may not be applicable
to patients who are more ill. As the practice of LDLT matures, it will be important to
continually reevaluate the morbidity associated with the operation and identify opportunities
to improve its outcomes.
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Table 1
Clavien system for the classification of negative outcomes in general surgery and solid
organ transplantation (adapted from references 8–10)
Grade 1 Any alteration from the ideal postoperative course, with complete recovery or which can be easily controlled and which fulfills the
following general characteristics:
(a) Not life threatening
(b) Not requiring use of drugs other than immunosuppressants, analgesics, antipyretics, antiinflammatory agents, antiemetics, drugs
required for urinary retention or lower urinary tract infection, arterial hypertension, hyperlipidemia or transient hyperglycemia
(c) Requiring only therapeutic procedures that can be performed at the bedside
(d) Postoperative bleeding requiring ≤3 units of blood transfusion
(e) Never associated with a prolongation of ICU stay or total hospital stay to more than twice the median stay for the procedure in
the population of the study
Grade 2 Any complication that is potentially life threatening or results in ICU stay >5 days, hospital stay >4 weeks for the recipient, but
which does not result in residual disability or persistent disease
Grade 3 Any complication with residual or lasting functional disability or development of malignant disease
Grade 4 Complications that lead to retransplantation (grade 4a) or death (grade 4b)
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Table 2
Characteristics of living donor (LDLT) and deceased donor liver transplant (DDLT)
recipients and LDLT living donors
Recipient characteristic LDLT (n = 384); mean (SD) or n (%)
DDLT (n = 216); mean (SD) or
n (%) p-Value*
Age 49.6 ± 10.7 51.4 ± 9.7 0.037
Sex 0.649
 Female 162 (42) 88 (41)
 Male 222 (58) 128 (59)
Ethnicity 0.822
 Hispanic 74 (19) 40 (19)
 Non-Hispanic 310 (81) 176 (81)
Race 0.368
 White 348 (91) 190 (88)
 African American 12 (3) 13 (6)
 Asian 15 (4) 7 (3)
 Other 9 (2) 6 (3)
Body mass index1 (kg/m2) 27 ± 5 27 ± 5 0.780
Diagnosis (multiple diagnoses possible)
 Hepatitis C diagnosis (HCV) 184 (48) 102 (47) 0.870
 Hepatocellular carcinoma diagnosis (HCC) 63 (16) 39 (18) 0.606
 Alcohol 52 (14) 32 (15) 0.666
 Cholestatic liver disease 71 (18) 39 (18) 0.895
 Noncholestatic cirrhosis other than HCV/alcohol 80 (21) 48 (22) 0.690
 Acute hepatic necrosis 6 (2) 9 (4) 0.050
 Metabolic disease 11 (3) 7 (3) 0.795
 Biliary atresia 3 (1) 0 (0) 0.557
 Malignancy other than HCC 11 (3) 5 (2) 0.688
 Other 9 (2) 3 (1) 0.551
MELD score at transplant1,2
 Categorical <0.0001
   6–10 80 (21) 22 (10)
   11–20 229 (60) 104 (48)
   21–30 48 (13) 45 (21)
   31–40 10 (3) 41 (19)
   Missing 16 (4) 4 (2)
 Continuous 15 ± 6 21 ± 9 <0.0001
Medical condition at transplant <0.0001
 Not hospitalized 335 (87) 130 (60)
 Hospitalized (not ICU) 42 (11) 48 (22)
 ICU 7 (2) 38 (18)
Severity
 Ventilator 5 (1) 15 (7) 0.0002
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Recipient characteristic LDLT (n = 384); mean (SD) or n (%)
DDLT (n = 216); mean (SD) or
n (%) p-Value*
 Ascites 222 (58) 160 (74) <0.0001
 Dialysis 5 (1) 14 (6) 0.001
Intraoperative
 Cold ischemia time (minutes)3 87 ± 94 441 ± 215 <0.0001
 Duration of recipient operation (minutes)1 511 ± 129 371 ± 96 <0.0001
LDLT living donor characteristics
 Age 37 ± 9.7
 Intraoperative hypotension (<100 mmHg)1 88 (23)
 Number of donor bile ducts
   1 205 (53)
   2 135 (35)
   ≥3 21 (5)
   Missing 23 (6)
Type of anastomosis
 Roux-en-Y 199 (52)
 Other 218 (47)
 Missing 5 (2)
Graft weight to recipient weight ratio <0.84 30 (8)
*
p-values comparing LDLT versus DDLT for continuous variables are based on t-tests, and for categorical variables are based on the chi-square or
Fisher's exact tests.
1
Values are missing in less than 5% for these variables.
2
MELD = model for end-stage liver disease.
3
Values are missing in 17%.
4
N = 378; graft weight was obtained from intraoperative measurement (47%), imaging (29%), or 0.6 × donor SLV (23%) and was missing in 1%.
Imaging volume was multiplied by 0.8, which was an empirical correction based on a regression analysis of actual versus imaging values.
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Table 7
Logistic regression models fitted to identify significant predictors of biliary leak (A),
biliary stricture (B) and Clavien grade 4 complications (C)
Adjusted odds ratio 95% confidence limits p-Value
A. Predictors of biliary leak1 (among LDLT only)
 LDLT case number:
   1–10 vs. >40 2.26 1.18 4.34 0.015
   11–20 vs. >40 1.77 0.94 3.34 0.079
   21–40 vs. >40 1.50 0.81 2.78 0.198
 HCV diagnosis 0.55 0.35 0.87 0.011
 No. of donor bile ducts from right lobe2:
   2 vs. 1 1.54 0.99 2.49 0.074
   ≥ 3 vs. 1 2.72 1.08 6.88 0.035
 Type of anastomosis: Roux-en-Y vs. other 0.71 0.45 1.13 0.150
B. Predictors of biliary stricture1 (among LDLT only)
 LDLT case number:
   1–10 vs. >40 3.32 1.45 7.57 0.004
   11–20 vs. >40 1.84 0.76 4.47 0.178
   21–40 vs. >40 2.37 1.06 5.31 0.036
 Cholestatic liver disease 2.10 1.03 4.27 0.040
 Duration of recipient operative procedure (per 100 min) 1.33 1.06 1.68 0.014
 Donor hypotension (<100 mmHg) 0.45 0.21 0.96 0.038
 No. of donor bile ducts from right lobe2:
   2 vs. 1 0.77 0.42 1.43 0.408
   ≥3 vs. 1 1.57 0.46 5.37 0.470
 Type of anastomosis: Roux-en-Y vs. other 0.49 0.27 0.88 0.017
C. Predictors of any grade 4 complication1 (LDLT and DDLT)
 DDLT vs. LDLT case number >40 0.78 0.38 1.64 0.517
 LDLT case number:
   1–10 vs. >40 2.33 1.06 5.11 0.036
   11–20 vs. >40 2.06 0.96 4.42 0.065
   21–40 vs. >40 0.96 0.42 2.22 0.921
1
All variables listed in Table 2 were tested for inclusion in each of the three models above. Among LDLT recipients, n = 78, 89, 109 and 108
transplants were performed for case numbers 1–10, 11–20, 21–40 and >40, respectively.
2
Missing values (n = 22) were assumed to be one bile duct.
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